Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer.
Excellent balance sheet and overvalued.
Share Price & News
How has Replimune Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 7R8 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 7R8 exceeded the German Biotechs industry which returned 8.4% over the past year.
Return vs Market: 7R8 exceeded the German Market which returned 13.7% over the past year.
Price Volatility Vs. Market
How volatile is Replimune Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Replimune Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: 7R8 (€15.3) is trading above our estimate of fair value (€12.55)
Significantly Below Fair Value: 7R8 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 7R8 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 7R8 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 7R8's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 7R8 is good value based on its PB Ratio (3.1x) compared to the DE Biotechs industry average (3.5x).
How is Replimune Group forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 7R8 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 7R8 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 7R8 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 7R8's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if 7R8's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 7R8's Return on Equity is forecast to be high in 3 years time
How has Replimune Group performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 7R8 is currently unprofitable.
Growing Profit Margin: 7R8 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 7R8's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 7R8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7R8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 7R8 has a negative Return on Equity (-22.01%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Replimune Group's financial position?
Financial Position Analysis
Short Term Liabilities: 7R8's short term assets ($190.9M) exceed its short term liabilities ($14.2M).
Long Term Liabilities: 7R8's short term assets ($190.9M) exceed its long term liabilities ($38.6M).
Debt to Equity History and Analysis
Debt Level: 7R8's debt to equity ratio (4.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 7R8's debt to equity ratio has reduced over the past 5 years.
Inventory Level: 7R8 has a high level of physical assets or inventory.
Debt Coverage by Assets: 7R8's debt is covered by short term assets (assets are 19.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 7R8 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 7R8 has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of -66% each year.
What is Replimune Group's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 7R8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 7R8's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 7R8's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 7R8's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 7R8's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Philip Astley-Sparke (48yo)
Mr. Philip Astley-Sparke, FSA, is a Co-founder of Replimune Group, Inc. and serves as its Executive Chairman since 2015. Mr. Astley-Sparke is Secretary and Treasurer at Replimune Group, Inc. and serves as ...
CEO Compensation Analysis
Compensation vs Market: Philip's total compensation ($USD1.81M) is above average for companies of similar size in the German market ($USD1.19M).
Compensation vs Earnings: Philip's compensation has increased whilst the company is unprofitable.
|Executive Chairman||0.08yrs||US$1.81m||3.7% $21.5m|
|Chief Operating Officer||4.3yrs||US$1.30m||2.87% $16.7m|
|Chief Financial Officer||0.2yrs||no data||no data|
|Chief Accounting Officer||0yrs||no data||no data|
|Chief Business Officer||4.3yrs||US$601.20k||0.31% $1.8m|
Experienced Management: 7R8's management team is considered experienced (4.3 years average tenure).
|Executive Chairman||0.08yrs||US$1.81m||3.7% $21.5m|
|Lead Independent Director||0.9yrs||US$158.83k||0.018% $105.6k|
|Independent Director||4.4yrs||US$151.26k||1.72% $10.0m|
|Independent Director||5.1yrs||US$144.48k||no data|
|Independent Director||4.8yrs||US$117.59k||no data|
|Independent Non-Executive Director||1.8yrs||US$262.53k||no data|
|Independent Director||2.6yrs||US$156.16k||no data|
|Independent Director||1.7yrs||US$262.65k||no data|
Experienced Board: 7R8's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 95.7%.
Replimune Group, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Replimune Group, Inc.
- Ticker: 7R8
- Exchange: DB
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$626.274m
- Listing Market Cap: US$580.306m
- Shares outstanding: 36.65m
- Website: https://www.replimune.com
Number of Employees
- Replimune Group, Inc.
- 18 Commerce Way
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|REPL||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 2018|
|7R8||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2018|
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. It is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 23:10|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.